United States: Summary of FDA Guidance on Determining Whether to Submit an ANDA or a 505(b)(2) Application

On October 13, 2017, the U.S. Food and Drug Administration (FDA) released for comment, by December 12, 2017, draft guidance for industry entitled, Determining Whether to Submit an ANDA or a 505(b)(2) Application.  The purpose of the guidance is to assist applicants in determining which one of the abbreviated approval pathways under the Federal Food, Drug and Cosmetic Act (FD&C Act) is appropriate for the submission of a marketing application to the FDA.

With the passage of the Hatch-Waxman amendments, the FD&C Act describes different routes for obtaining approval of four categories of drug applications:  (1) a "stand alone NDA (New Drug Application);" (2) a § 505(b)(2) application; (3) an Abbreviated New Drug Application (ANDA) for a duplicate of a previously approved drug product; and (4) a petitioned ANDA, a type of ANDA for a drug product that differs in certain respects from the Reference Listed Drug (RLD).  The guidance briefly expands upon these four different pathways and discusses the regulatory and scientific considerations for determining whether to file an ANDA or § 505(b)(2) application. 

Abbreviated Approval Pathways

  • Stand-Alone NDA (submitted under § 505(b)(1) and approved under § 505(c) of the FD&C Act)

This application contains "full reports of investigations of safety and effectiveness that were conducted by or for the applicant or for which the applicant has a right of reference or use."

  • 505(b)(2) Application (submitted under § 505(b)(1), approved under § 505(c))

This application contains "full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use."  A § 505(b)(2) application may rely on the FDA's safety and/or efficacy findings for a listed drug only to the extent that the proposed product of the §  505(b)(2) application shares characteristics with the listed drug, such as active ingredient, dosage form, route of administration, strength, indication, and/or conditions of use. To the extent that the listed drug and the proposed § 505(b)(2) drug differ, for example, in dosage form or increased bioavailability over the listed drug, the applicant must include sufficient data to support those differences. In particular, the applicant is expected to establish a bridge (e.g., by using comparative bioavailability data) between the proposed drug product and each listed drug upon which the applicant seeks to rely to demonstrate that such reliance is scientifically justified.  A § 505(b)(2) application will not necessarily be rated as therapeutically equivalent to the RLD upon approval.

  • ANDAs (submitted and approved under § 505(j))

An ANDA applicant must demonstrate that the proposed generic drug product and the applicable RLD are the same with respect to their proposed active ingredient(s), dosage form, route of administration, strength, previously approved conditions of use, and labeling (with certain exceptions).  An ANDA must also include sufficient information (1) to demonstrate that the proposed product is bioequivalent to the RLD, and (2) to ensure the product's identity, strength, quality, and purity.  An ANDA relies on the FDA's finding of safety and effectiveness for an RLD and, as a result, safety and efficacy studies are not submitted in the ANDA. 

  • Petitioned ANDAs (submitted and approved under § 505(j))

A petitioned ANDA is a type of ANDA for a drug product that differs from the RLD in its dosage form, route of administration, strength, or active ingredient (in a product with more than 1 active ingredient), and for which the FDA has determined, in response to a suitability petition under § 505(j)(2)(c), that safety and efficacy studies are not necessary for the proposed drug product.

  Regulatory Considerations for ANDAs and § 505(b)(2) Applications

  • Duplicates

The FDA generally will refuse a § 505(b)(2) application for a drug that is a duplicate of a listed drug and eligible for approval under § 505(j) of the FD&C Act.  Unless a duplicate drug product is approved by the FDA after a § 505(b)(2) application is submitted, but before the § 505(b)(2) application is approved, the FDA will refuse the § 505(b)(2) application when it is a duplicate of a listed drug. 

  • Petitioned ANDAs

An applicant may submit a suitability petition to the FDA requesting permission to submit an ANDA for a generic product that differs from the RLD in its route of administration, dosage form, or strength, or that has one different active ingredient in a fixed combination drug product.  The FDA generally will approve such a suitability petition unless, among other things, (1) "it determines that the safety and effectiveness of the proposed change from the RLD cannot be adequately evaluated without data from investigations that exceed what may be required for an ANDA," or (2) the petition is for a drug product for which a pharmaceutical equivalent has been approved in an NDA, including for example, a § 505(b)(2) application that referenced the same RLD named in the suitability petition.

  • Bundling

In circumstances where an applicant is seeking approval for multiple drug products containing the same ingredient,  where only some of the products are listed in the Orange Book as RLDs, the FDA has permitted an applicant to submit a single "bundled" § 505(b)(2) application for all of the products, even though applications referencing the Orange Book-listed products would qualify for approval under the § 505(j) pathway. 

 Scientific Considerations for ANDAs and § 505(b)(2) Applications

  • Limited Confirmatory Studies

If data are needed to establish safety or efficacy of a proposed ANDA product, then an ANDA application is not appropriate.  Data from limited confirmatory testing may be submitted in an ANDA, however, to show that the characteristics that make the proposed drug product different from the listed drug do not alter its safety and effectiveness. 

  • Active Ingredient Sameness Evaluation

If the active ingredient in an applicant's proposed drug product cannot be demonstrated to be the same as the active ingredient in the RLD by using the information and data that must be submitted in connection with an ANDA, the drug product should not be submitted for approval in an ANDA.

  • Intentional Differences Between the Proposed Drug Product and an RLD

    • Formulation Differences

      Certain differences in inactive ingredients (formulation differences) are permissible with a justification demonstrating that the safety and effectiveness of the proposed drug product is not adversely affected by the differences.  Regulations limit the permissible changes to inactive ingredients for parenteral, ophthalmic, and otic drug products.  An applicant should consider submitting a § 505(b)(2) application if the proposed drug product contains either changes to its formulation that are not permissible in an ANDA or a novel excipient that has not been used in an FDA-approved drug product and the safety of which cannot be established without clinical testing.
  • Bioequivalence and/or Bioavailability Differences

    An ANDA must contain information to show that the proposed drug product is bioequivalent to the RLD: the rate and extent of absorption of the proposed drug and RLD do not show a significant difference when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses.  The FDA noted, however, that "[(w]here there is an intentional difference in rate (e.g., in certain extended-release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action."

    An application for a proposed drug product where the rate and/or extent of absorption exceed, or are otherwise different from, the § 505(j) standards for bioequivalence may be submitted under the § 505(b)(2) pathway and may require studies to show the safety and efficacy of the proposed product at the different rate and/or extent of delivery.  However, the FDA generally will not accept a § 505(b)(2) application if the only difference from the RLD is that the extent to or rate at which the proposed product's active ingredient is absorbed or otherwise made available at the site of action is less than that of the RLD.
  • Conditions of Use Differences

    A § 505(j) application must include a statement that the conditions of use prescribed, recommended, or suggested in the labeling for the proposed drug product have been previously approved for the RLD.  If the proposed drug product has added a new indication, the application cannot be approved as an ANDA.  However, the FDA will not refuse to approve an ANDA whose proposed labeling excludes conditions of use approved for the RLD because of patents or exclusivity.
  • Labeling Differences

    An ANDA must contain "information to show that the labeling proposed for the new drug is the same as the labelling for the [RLD] . . . except for changes required because of differences approved under a [suitability petition] . . . or because the new drug and the [RLD] are produced or distributed by different manufacturers."  An ANDA is not appropriate if the proposed drug product would have a new indication or a new dosing regimen as compared to the RLD.  Further, if the differences between the products are such that they would require safety or efficacy investigations for the proposed product or necessitate such significant labeling differences that the labeling no longer satisfies the "same" labeling requirement, the proposed product should be submitted under § 505(b).
  • Other Differences

    Drug products that differ considerably from the RLD are generally not candidates for the § 505(j) pathway.  In its assessment, the FDA examines both individual differences between the products and the combined effects of those differences. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
11 Dec 2018, Conference, Washington, DC, United States

Finnegan partner Li Feng will present "How to Read & Write Patents and Scientific Publications"at the 72nd annual Scientific Meeting & Technology Showcase, hosted by the Society of Cosmetic Chemists.

11 Dec 2018, Conference, Washington, DC, United States

Finnegan is a Conference App sponsor of DeviceTalks West, hosted by MassDevice. The program will take place at the Hilton Orange County hotel in Costa Mesa, California.

12 Dec 2018, Seminar, Washington, DC, United States

Finnegan partner Anthony Tridico will present “U.S. Case Law Update” during the Chartered Institute of Patent Attorneys’ Patent Case Law program.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions